Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021

Esther Kissling; Mariette Hooiveld; Ivan Martinez-Baz; Clara Mazagatos; Naoma William; Ana Maria Vilcu; Marjolein N. Kooijman; Maja Ilic; Lisa Domegan; Ausenda Machado; Simon De Lusignan; Mihaela Lazar; Adam Meijer; Mia Brytting; Itziar Casado; Amparo Larrauri; Josephine L.K. Murray; Sylvie Behillil; Brechje De Gier; Ivan Mlinaric; Joan O'Donnell; Ana Paula Rodrigues; Ruby Tsang; Olivia Timnea; Marit de Lange; Maximilian Riess; Jesus Castilla; Francisco Pozo; Mark Hamilton; Alessandra Falchi; Mirjam J. Knol; Sanja Kurecic Filipovic; Linda Dunford; Raquel Guiomar; Jade Cogdale; Carmen Cherciu; Tessa Jansen; Theresa Enkirch; Luca Basile; Jeff Connell; Veronica Gomez; Virginia Sandonis Martin; Sabrina Bacci; Angela M.C. Rose; Lucia Pastore Celentano; Marta Valenciano; I-MOVE-COVID-19 primary care study team

doi:10.2807/1560-7917.ES.2022.27.21.2101104

Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021

Esther Kissling^*, Mariette Hooiveld, Ivan Martinez-Baz, Clara Mazagatos, Naoma William, Ana Maria Vilcu, Marjolein N. Kooijman, Maja Ilic, Lisa Domegan, Ausenda Machado, Simon De Lusignan, Mihaela Lazar, Adam Meijer, Mia Brytting, Itziar Casado, Amparo Larrauri, Josephine L.K. Murray, Sylvie Behillil, Brechje De Gier, Ivan MlinaricJoan O'Donnell, Ana Paula Rodrigues, Ruby Tsang, Olivia Timnea, Marit de Lange, Maximilian Riess, Jesus Castilla, Francisco Pozo, Mark Hamilton, Alessandra Falchi, Mirjam J. Knol, Sanja Kurecic Filipovic, Linda Dunford, Raquel Guiomar, Jade Cogdale, Carmen Cherciu, Tessa Jansen, Theresa Enkirch, Luca Basile, Jeff Connell, Veronica Gomez, Virginia Sandonis Martin, Sabrina Bacci, Angela M.C. Rose, Lucia Pastore Celentano, Marta Valenciano, I-MOVE-COVID-19 primary care study team

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

Introduction: In July and August 2021, the SARS-CoV-2 Delta variant dominated in Europe. Aim: Using a multicentre test-negative study, we measured COVID-19 vaccine effectiveness (VE) against symptomatic infection.

Methods: Individuals with COVID-19 or acute respiratory symptoms at primary care/community level in 10 European countries were tested for SARS-CoV-2. We measured complete primary course overall VE by vaccine brand and by time since vaccination.

Results: Overall VE was 74% (95% CI: 69-79), 76% (95% CI: 71-80), 63% (95% CI: 48-75) and 63% (95% CI: 16-83) among those aged 30-44, 45-59, 60-74 and ≥ 75 years, respectively. VE among those aged 30-59 years was 78% (95% CI: 75-81), 66% (95% CI: 58-73), 91% (95% CI: 87-94) and 52% (95% CI: 40-61), for Comirnaty, Vaxzevria, Spikevax and COVID-19 Vaccine Janssen, respectively. VE among people 60 years and older was 67% (95% CI: 52-77), 65% (95% CI: 48-76) and 83% (95% CI: 64-92) for Comirnaty, Vaxzevria and Spikevax, respectively. Comirnaty VE among those aged 30-59 years was 87% (95% CI: 83-89) at 14-29 days and 65% (95% CI: 56-71%) at ≥ 90 days between vaccination and onset of symptoms.

Conclusions: VE against symptomatic infection with the SARS-CoV-2 Delta variant varied among brands, ranging from 52% to 91%. While some waning of the vaccine effect may be present (sample size limited this analysis to only Comirnaty), protection was 65% at 90 days or more between vaccination and onset.

Original language	English
Article number	A1
Number of pages	13
Journal	Eurosurveillance
Volume	27
Issue number	21
DOIs	https://doi.org/10.2807/1560-7917.ES.2022.27.21.2101104
Publication status	Published - 26 May 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2807/1560-7917.ES.2022.27.21.2101104Licence: CC BY

Kissling-2022-Effectiveness-of-complete-primary-Eurosurv-27-21-2-CCBY
This article is copyright of the authors or their affiliated institutions, 2022. This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence and indicate if changes were made.
Final published version, 628 KBLicence: CC BY

Fingerprint

Dive into the research topics of 'Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021'. Together they form a unique fingerprint.

Cite this

Kissling, E., Hooiveld, M., Martinez-Baz, I., Mazagatos, C., William, N., Vilcu, A. M., Kooijman, M. N., Ilic, M., Domegan, L., Machado, A., De Lusignan, S., Lazar, M., Meijer, A., Brytting, M., Casado, I., Larrauri, A., Murray, J. L. K., Behillil, S., De Gier, B., ... I-MOVE-COVID-19 primary care study team (2022). Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021. Eurosurveillance, 27(21), Article A1. https://doi.org/10.2807/1560-7917.ES.2022.27.21.2101104

@article{187b6a5942034b3596d7069fe86b9b2d,

title = "Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021",

abstract = "Introduction: In July and August 2021, the SARS-CoV-2 Delta variant dominated in Europe. Aim: Using a multicentre test-negative study, we measured COVID-19 vaccine effectiveness (VE) against symptomatic infection. Methods: Individuals with COVID-19 or acute respiratory symptoms at primary care/community level in 10 European countries were tested for SARS-CoV-2. We measured complete primary course overall VE by vaccine brand and by time since vaccination. Results: Overall VE was 74% (95% CI: 69-79), 76% (95% CI: 71-80), 63% (95% CI: 48-75) and 63% (95% CI: 16-83) among those aged 30-44, 45-59, 60-74 and ≥ 75 years, respectively. VE among those aged 30-59 years was 78% (95% CI: 75-81), 66% (95% CI: 58-73), 91% (95% CI: 87-94) and 52% (95% CI: 40-61), for Comirnaty, Vaxzevria, Spikevax and COVID-19 Vaccine Janssen, respectively. VE among people 60 years and older was 67% (95% CI: 52-77), 65% (95% CI: 48-76) and 83% (95% CI: 64-92) for Comirnaty, Vaxzevria and Spikevax, respectively. Comirnaty VE among those aged 30-59 years was 87% (95% CI: 83-89) at 14-29 days and 65% (95% CI: 56-71%) at ≥ 90 days between vaccination and onset of symptoms. Conclusions: VE against symptomatic infection with the SARS-CoV-2 Delta variant varied among brands, ranging from 52% to 91%. While some waning of the vaccine effect may be present (sample size limited this analysis to only Comirnaty), protection was 65% at 90 days or more between vaccination and onset.",

author = "Esther Kissling and Mariette Hooiveld and Ivan Martinez-Baz and Clara Mazagatos and Naoma William and Vilcu, {Ana Maria} and Kooijman, {Marjolein N.} and Maja Ilic and Lisa Domegan and Ausenda Machado and {De Lusignan}, Simon and Mihaela Lazar and Adam Meijer and Mia Brytting and Itziar Casado and Amparo Larrauri and Murray, {Josephine L.K.} and Sylvie Behillil and {De Gier}, Brechje and Ivan Mlinaric and Joan O'Donnell and Rodrigues, {Ana Paula} and Ruby Tsang and Olivia Timnea and {de Lange}, Marit and Maximilian Riess and Jesus Castilla and Francisco Pozo and Mark Hamilton and Alessandra Falchi and Knol, {Mirjam J.} and Filipovic, {Sanja Kurecic} and Linda Dunford and Raquel Guiomar and Jade Cogdale and Carmen Cherciu and Tessa Jansen and Theresa Enkirch and Luca Basile and Jeff Connell and Veronica Gomez and Martin, {Virginia Sandonis} and Sabrina Bacci and Rose, {Angela M.C.} and Celentano, {Lucia Pastore} and Marta Valenciano and {I-MOVE-COVID-19 primary care study team}",

note = "This project received funding from the European Centre for Disease Prevention and Control (ECDC) under the contract ECD.11486. This project has received funding from the European Union{\textquoteright}s Horizon 2020 research and innovation programme under grant agreement No 101003673.",

year = "2022",

month = may,

day = "26",

doi = "10.2807/1560-7917.ES.2022.27.21.2101104",

language = "English",

volume = "27",

journal = "Eurosurveillance",

issn = "1025-496X",

publisher = "European Centre for Disease Prevention and Control (ECDC)",

number = "21",

}

Kissling, E, Hooiveld, M, Martinez-Baz, I, Mazagatos, C, William, N, Vilcu, AM, Kooijman, MN, Ilic, M, Domegan, L, Machado, A, De Lusignan, S, Lazar, M, Meijer, A, Brytting, M, Casado, I, Larrauri, A, Murray, JLK, Behillil, S, De Gier, B, Mlinaric, I, O'Donnell, J, Rodrigues, AP, Tsang, R, Timnea, O, de Lange, M, Riess, M, Castilla, J, Pozo, F, Hamilton, M, Falchi, A, Knol, MJ, Filipovic, SK, Dunford, L, Guiomar, R, Cogdale, J, Cherciu, C, Jansen, T, Enkirch, T, Basile, L, Connell, J, Gomez, V, Martin, VS, Bacci, S, Rose, AMC, Celentano, LP, Valenciano, M & I-MOVE-COVID-19 primary care study team 2022, 'Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021', Eurosurveillance, vol. 27, no. 21, A1. https://doi.org/10.2807/1560-7917.ES.2022.27.21.2101104

Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021. / Kissling, Esther; Hooiveld, Mariette; Martinez-Baz, Ivan et al.
In: Eurosurveillance, Vol. 27, No. 21, A1, 26.05.2022.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe

T2 - multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021

AU - Kissling, Esther

AU - Hooiveld, Mariette

AU - Martinez-Baz, Ivan

AU - Mazagatos, Clara

AU - William, Naoma

AU - Vilcu, Ana Maria

AU - Kooijman, Marjolein N.

AU - Ilic, Maja

AU - Domegan, Lisa

AU - Machado, Ausenda

AU - De Lusignan, Simon

AU - Lazar, Mihaela

AU - Meijer, Adam

AU - Brytting, Mia

AU - Casado, Itziar

AU - Larrauri, Amparo

AU - Murray, Josephine L.K.

AU - Behillil, Sylvie

AU - De Gier, Brechje

AU - Mlinaric, Ivan

AU - O'Donnell, Joan

AU - Rodrigues, Ana Paula

AU - Tsang, Ruby

AU - Timnea, Olivia

AU - de Lange, Marit

AU - Riess, Maximilian

AU - Castilla, Jesus

AU - Pozo, Francisco

AU - Hamilton, Mark

AU - Falchi, Alessandra

AU - Knol, Mirjam J.

AU - Filipovic, Sanja Kurecic

AU - Dunford, Linda

AU - Guiomar, Raquel

AU - Cogdale, Jade

AU - Cherciu, Carmen

AU - Jansen, Tessa

AU - Enkirch, Theresa

AU - Basile, Luca

AU - Connell, Jeff

AU - Gomez, Veronica

AU - Martin, Virginia Sandonis

AU - Bacci, Sabrina

AU - Rose, Angela M.C.

AU - Celentano, Lucia Pastore

AU - Valenciano, Marta

AU - I-MOVE-COVID-19 primary care study team

N1 - This project received funding from the European Centre for Disease Prevention and Control (ECDC) under the contract ECD.11486. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003673.

PY - 2022/5/26

Y1 - 2022/5/26

N2 - Introduction: In July and August 2021, the SARS-CoV-2 Delta variant dominated in Europe. Aim: Using a multicentre test-negative study, we measured COVID-19 vaccine effectiveness (VE) against symptomatic infection. Methods: Individuals with COVID-19 or acute respiratory symptoms at primary care/community level in 10 European countries were tested for SARS-CoV-2. We measured complete primary course overall VE by vaccine brand and by time since vaccination. Results: Overall VE was 74% (95% CI: 69-79), 76% (95% CI: 71-80), 63% (95% CI: 48-75) and 63% (95% CI: 16-83) among those aged 30-44, 45-59, 60-74 and ≥ 75 years, respectively. VE among those aged 30-59 years was 78% (95% CI: 75-81), 66% (95% CI: 58-73), 91% (95% CI: 87-94) and 52% (95% CI: 40-61), for Comirnaty, Vaxzevria, Spikevax and COVID-19 Vaccine Janssen, respectively. VE among people 60 years and older was 67% (95% CI: 52-77), 65% (95% CI: 48-76) and 83% (95% CI: 64-92) for Comirnaty, Vaxzevria and Spikevax, respectively. Comirnaty VE among those aged 30-59 years was 87% (95% CI: 83-89) at 14-29 days and 65% (95% CI: 56-71%) at ≥ 90 days between vaccination and onset of symptoms. Conclusions: VE against symptomatic infection with the SARS-CoV-2 Delta variant varied among brands, ranging from 52% to 91%. While some waning of the vaccine effect may be present (sample size limited this analysis to only Comirnaty), protection was 65% at 90 days or more between vaccination and onset.

AB - Introduction: In July and August 2021, the SARS-CoV-2 Delta variant dominated in Europe. Aim: Using a multicentre test-negative study, we measured COVID-19 vaccine effectiveness (VE) against symptomatic infection. Methods: Individuals with COVID-19 or acute respiratory symptoms at primary care/community level in 10 European countries were tested for SARS-CoV-2. We measured complete primary course overall VE by vaccine brand and by time since vaccination. Results: Overall VE was 74% (95% CI: 69-79), 76% (95% CI: 71-80), 63% (95% CI: 48-75) and 63% (95% CI: 16-83) among those aged 30-44, 45-59, 60-74 and ≥ 75 years, respectively. VE among those aged 30-59 years was 78% (95% CI: 75-81), 66% (95% CI: 58-73), 91% (95% CI: 87-94) and 52% (95% CI: 40-61), for Comirnaty, Vaxzevria, Spikevax and COVID-19 Vaccine Janssen, respectively. VE among people 60 years and older was 67% (95% CI: 52-77), 65% (95% CI: 48-76) and 83% (95% CI: 64-92) for Comirnaty, Vaxzevria and Spikevax, respectively. Comirnaty VE among those aged 30-59 years was 87% (95% CI: 83-89) at 14-29 days and 65% (95% CI: 56-71%) at ≥ 90 days between vaccination and onset of symptoms. Conclusions: VE against symptomatic infection with the SARS-CoV-2 Delta variant varied among brands, ranging from 52% to 91%. While some waning of the vaccine effect may be present (sample size limited this analysis to only Comirnaty), protection was 65% at 90 days or more between vaccination and onset.

U2 - 10.2807/1560-7917.ES.2022.27.21.2101104

DO - 10.2807/1560-7917.ES.2022.27.21.2101104

M3 - Article

C2 - 35620997

AN - SCOPUS:85130872682

SN - 1025-496X

VL - 27

JO - Eurosurveillance

JF - Eurosurveillance

IS - 21

M1 - A1

ER -

Kissling E, Hooiveld M, Martinez-Baz I, Mazagatos C, William N, Vilcu AM et al. Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021. Eurosurveillance. 2022 May 26;27(21):A1. doi: 10.2807/1560-7917.ES.2022.27.21.2101104